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ABSTRACT: Trefoil factor 3 (TFF3), cholinesterase activity (ChE activity) and homocysteine (Hcy) play critical
roles in modulating recognition, learning and memory in neurodegenerative diseases, such as
Parkinson's disease dementia (PDD) and vascular parkinsonism with dementia (VPD). However, whether they
can be used as reliable predictors to evaluate the severity and progression of PDD and VPD remains largely
unknown. Methods: We performed a cross-sectional study that included 92 patients with PDD, 82 patients with
VPD and 80 healthy controls. Serum levels of TFF3, ChE activity and Hcy were measured. Several scales were
used to rate the severity of PDD and VPD. Receivers operating characteristic (ROC) curves were applied to map
the diagnostic accuracy of PDD and VPD patients compared to healthy subjects. Results: Compared with healthy
subjects, the serum levels of TFF3 and ChE activity were lower, while Hcy was higher in the PDD and VPD
patients. These findings were especially prominent in male patients. The three biomarkers displayed differences
between PDD and VPD sub-groups based on genders and UPDRS (III) scores’ distribution. Interestingly, these
increased serum Hcy levels were significantly and inversely correlated with decreased TFF3/ChE activity levels.
There were significant correlations between TFF3/ChE activity/Hcy levels and PDD/VPD severities, including
motor dysfunction, declining cognition and mood/gastrointestinal symptoms. Additionally, ROC curves for the
combination of TFF3, ChE activity and Hcy showed potential diagnostic value in discriminating PDD and VPD
patients from healthy controls. Conclusions: Our findings suggest that serum TFF3, ChE activity and Hcy levels
may underlie the pathophysiological mechanisms of PDD and VPD. As the race to find biomarkers or predictors
for these diseases intensifies, a better understanding of the roles of TFF3, ChE activity and Hcy may yield insights
into the pathogenesis of PDD and VPD.
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Parkinson’s disease (PD) and vascular parkinsonism (VP)

are among the most common neurodegenerative disorders.
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Longitudinal studies have shown that many PD patients
will eventually develop into PD with dementia (PDD),
leading to poorer activities of daily living and increased
caregiver burden [1, 2]. Although patients with VP show
different neuro-pathogenesis than patients with PD, they
typically present with similar clinical characteristics as
PD [3]. For instance, in the later stages, both diseases
present severe non-motor dysfunction, including impaired
cognition and depression [4-6]. Compared with patients
with PD or healthy controls, VP patients display more
profound cognitive declines with impaired attention [7].
However, risk factors and time to onset for PDD and VP
dementia (VPD) vary from patient to patient, reflecting
the inter-individual heterogeneity underlying the different
pathological substrates of PDD and VPD [3, 8]. Although

these risk factors of ongoing PDD and VPD have not been
clearly defined, several clinical predictors have been
suggested. One population-based cohort study indicated
that low CSF levels of -amyloid 42 (A42) at PD
diagnosis predict substantial increased risk of early
progression to dementia in patients with incident PD [9].
Several lines of evidence have also indicated that uric acid
(UA) is a major natural antioxidant that might have
neuroprotective properties [10, 11]. Low serum UA levels
have been associated with worse cognitive functioning
later in life and also with higher risk and faster
progression of PD and VP [11, 12].

Table 1. Demographic, motor, and non-motor parameters.
Healthy
subjects

PDD
Clinical parameters

VPD

Mean (SD)

Min

Max

Mean (SD)

Male n (%)

49(53.3)

/

/

44(55)

/

Female n (%)

43(46.7)

/

/

36(45)

Age (years)

65.73(11.18)

56

88

H&Y
MMSE
UPDRS

2.85(1.23)
21.72(3.94)
50.92(23.13)

1
6
17

5
24
96

UPRDRS(I)

3.70(2.05)

1

UPRDRS(II)

18.17(9.64)

3

UPRDRS(III)

27.02(11.04)

2.03(2.50)
86.77(53.47)
Cardiovascular
4.06 (2.90)
Sleep/Fatigue
17.50(9.58)
Mood
19.30(14.41)
Perceptual problem 2.87(4.48)
Attention/memory 11.27(7.79)
Gastrointestina
9.35(6.54)
Urinar
8.30(8.16)
Sexual function
5.45(6.23)
Miscellaneous
8.67(10.25)

Gender (n)

Mean (SD)

Min

Max

/

45(54.8)

/

/

/

/

37(45.2)

/

/

64.43(7.10)

50

82

70.29(9.87)

65

83

/
/
/

/
/
/

/
/
/

2.68(1.05)
17.34(5.04)
44.36(19.03)

1
1
16

5
23
83

12

/

/

/

3.79(3.08)

0

14

45

/

/

/

16.57(8.79)

3

40

9

51

/

/

/

22.49(9.58)

5

51

0
20
0
0
3
0
0
0
0
0
0

9
188
12
36
54
18
30
28
32
18
36

/
/
/
/
/
/
/
/
/
/
/

/
/
/
/
/
/
/
/
/
/
/

/
/
/
/
/
/
/
/
/
/
/

1.52(1.81)
103.22(44.42)
4.96(3.95)
19.64(8.90)
23.30(12.51)
3.47(5.92)
14.51(7.11)
10.15(7.37)
11.18(7.93)
8.41(7.69)
7.61(7.20)

0
30
0
2
0
0
0
0
0
0
0

7
235
18
46
56
26
30
31
36
24
38

252.6(58.52)

206.44

291.14

/

/

/

275.06(65.77) 223.35 305.21

4.05(3.40)

0.5

15

/

/

/

UPRDRS(Ⅵ)

NMSS (total)

Daily dose of
L-Dopa (mg)
Disease
Duration

Min Max

3.53(3.36)

0.5

11

SD, standard deviation; UPDRS, Unified Parkinson’s disease rating scale; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state
examination and NMSS, non-motor symptoms scale for Parkinson’s disease.
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Trefoil factor 3 (TFF3) is a neuropeptide secreted by
secretory epithelial cells principally in the gastrointestinal
tract and different cerebral regions including the
hypothalamus, pituitary, hippocampi, temporal cortices
and cerebellum [13-15]. Recent studies have shown that
TFF3 may facilitate learning, objective recognition and
retention of memory [16]. Low TFF3 in CSF is a
predictive factor for brain atrophy and its potential role in
the pathogenesis of Alzheimer disease (AD) has been
suggested [17]. Multiple lines of evidence indicate that
TFF3 is associated with vascular epithelial restitution [18]
and anti-inflammatory effects and that it exerts protective
effects against age-related diseases [17, 19].
Homocysteine (Hcy), a sulfur-containing amino acid
produced by the interaction of cysteine and methionine, is
closely related to cognitive impairment [20-23] and high
levels can damage endothelial cells [24]. Although both
TFF3 and Hcy are correlated with endothelial cell
efficiency and declining cognition, the association of
TFF3/Hcy levels with the severity of dementia in PD and
VP has not been systemically evaluated.
Cholinesterase activity (ChE activity), including
acetylcholinesterase (AChE) activity and butyrylcholinesterase (BuChE) activity, has been studied as a
marker for AD and plays a crucial role in preserving
cognitive function [25, 26]. Previous studies have found
that ChE activity levels reflect metabolic alterations
associated with dementia, but they have not yielded
information for their differential diagnoses [27, 28].
Several lines of evidence suggest that ChE/AChE
activities contribute to regulating vascular endothelial
dysfunction [29], suppressing inflammation and
improving recovery prospects in cerebral ischemic
diseases [30].
TFF3, Hcy and ChE activity modulate cognitive
function and are
associated with vascular function,
inflammation and oxidative stress [17, 20, 24, 26, 29].
Vascular damage and chronic inflammation are observed
in PDD and VPD patients [31-34]. Therefore, it is
promising to investigate their levels and roles in PDD and
VPD. The primary aim of this study was to compare
serum levels of TFF3/ChE activity/Hcy among healthy
subjects and patients with PDD and VPD. The secondary
aim was to evaluate whether serum levels of TFF3/ChE
activity/Hcy are associated with motor/non-motor
dysfunctions in PDD and VPD. Lastly, we intended to
determine the diagnostic value of serum levels of
TFF3/ChE activity/Hcy in patients with PDD and VPD.
Our study will provide a better understanding of the roles
of TFF3, ChE activity and Hcy in the pathogenesis of
PDD and VPD.
MATERILAS AND METHODS

Patients and Ethics Statement
This cross-sectional study was performed in the
Department of Neurology of the Third Affiliated Hospital
of Sun Yat-sen University, Guangzhou, P. R. China. From
November 2013 to October 2016, a total of 174 dementia
patients (PDD and VPD patients) were recruited into this
study. A total of 92 PD patients with dementia (49 males
and 43 females, Table 1) were enrolled in this study.
Diagnosis of PDD patients was carried out consensually
between 2 clinicians using the diagnostic criteria for PDD
[35]. An additional 82 VPD patients with dementia (45
males and 37 females, Table 1) were recruited based upon
the consensus criteria for the clinical diagnosis of VP.
MMSE scores in all patients were less than 25. A total of
80 healthy subjects (44 males and 36 females, Table 1)
were recruited from the outpatient setting as the control
group. All the outpatients were recruited from the Medical
Examination Centre in the Third Affiliated Hospital of
Sun Yat-sen University. Exclusion criteria for the study
included hypertension, cerebral ischemia, cardiovascular
disease, diabetes, renal dysfunction diabetes or
psychiatric diseases (e.g. depression, drug addiction).
Patients were also excluded if they presented with
abnormal prostate carcinoma-related mediators, including
prostate-specific antigen (PSA), carcinoembryonic
antigen (CEA) or alpha-fetoprotein (AFP).
This study was approved by the local Ethics
Committee of the Third Affiliated Hospital of Sun Yat-sen
University and was conducted in accordance with the
principles outlined in the Declaration of Helsinki and the
National Institutes of Health Human Subjects Policies and
Guidance released on January and December 23, 1999,
respectively. All participants provided written consent for
the investigation and their consent to measure levels of
serum TFF3, ChE activity and Hcy. Patients with PDD
and VPD also completed additional disease-specific
standard assessments, which were all conducted in a
blinded manner.
Study Design
Experienced neurologists were recruited to perform the
evaluations and completed the neurological examinations
for both the treatment and control participants. All
patients with PDD included in this study satisfied the
criteria presented in Emre’s reports [35]. PDD exclusion
criteria were as follows: (1) PDD patients with disability
due to neurological disorders other than PDD, such as
cerebrovascular disease, sequelae or psychosis; (2) PDD
patients with somatic diseases that could have a potential
effect on NMS (e.g., pain syndromes, advanced diabetes
mellitus, malignancy, renal, hepatic/heart failure, severe
anemia, any other acute/chronic debilitating or life-
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threatening diseases/states); (3) MMSE scores higher than
25 (25 excluded); or (4) refusal to provide informed
consent. All patients with VPD in this study fulfilled the
criteria presented in Dunet and Zijlmans’ reports [31, 36]
as follows: (1) parkinsonism, defined as bradykinesia and
at least one of the following: resting tremor, rigidity or
postural instability; (2) cerebrovascular disease, defined
as evidence of relevant cerebrovascular disease by brain
imaging or the presence of focal signs or symptoms that
are consistent with stroke; (3) a relationship between these
first two criteria and the following: an acute or delayed
progressive onset of parkinsonism (within 1 year) after
stroke with evidence of infarcts in or near areas that
increase the basal ganglion motor output or decrease the
thalamocortical drive directly OR an insidious onset of
parkinsonism with extensive subcortical white matter
lesions, bilateral symptoms at the onset and the presence
of early shuffling gait or early cognitive dysfunction. All
subjects completed the following battery of standard
assessment measures: a standard demography form, the
unified Parkinson’s disease rating scale (UPDRS) [37]
and the modified Hoehn and Yahr staging scale (H&Y)
[38]. The UPDRS(I) ‘mentation’ and UPDRS(II) ‘daily
life’ subscales were used to evaluate psychiatric
dysfunction and disease severity. The UPDRS (III) ‘motor’
and H&Y subscales were used to evaluate motor
dysfunction and disease severity. The degree of nonmotor symptoms (NMS) in every patient was measured
by the NMS scale (NMSS) [5, 39, 40]. Cognitive abilities
were evaluated with the Mini-Mental State Examination
(MMSE) [5, 41]. All scales were available and validated

for the Chinese population [5]. According to Reinoso and
Oosterveld’s studies, we divided the PDD and VPD into
three sub-groups with UPDRS-III scores respectively,
namely mild (≤30 points, 28 cases for PDD, 21 cases for
VPD) , moderate ( 31-50 points, 39 cases for PDD, 36
cases for VPD) and severe ( >50 points, 25 cases for PDD,
25 cases for VPD) [42, 43]. All participants were scanned
using magnetic resonance imaging (MRI) and
representative MRIs for normal controls/PDD/VPD
patients are shown in Figure 3. Demographic and clinical
data for participants are shown in Table 1.

Blood sampling measurement
Venous blood samples for TFF3, ChE activity and Hcy
measurements were obtained from all subjects in the study.
5 ml of blood was drawn from the patients under fasting
state in the morning and all of blood measurements were
replicated thrice. The serum was separated for a total of
1 h by centrifugation at 3,000 rpm for 10 min. Separated
sera were stored at –30°C until laboratory evaluation took
place. Serum levels of TFF3 were measured using
commercial ELISA kits purchased from R&D Systems
(Minneapolis, MN, USA) and performed in accordance
with the manufacturer’s instructions. ChE activity levels
were measured using the method of Ellman et al. [44].
Serum levels of Hcy were determined using a solid-phase
competitive chemiluminescent enzyme immunoassay
[20].

Table 2. Comparison of age, MMSE, TFF3, Hcy and ChE activity among PDD, VPD and normal healthy subjects.
Tukey’s
Variable

PDD

VPD

Control

t Value

p Value
PDD/VPD

PDD/Control

VPD/Control

Age

65.73±11.18

70.29±9.87

64.43±7.10

2.925

0.008**

0.007**

0.295

0.005**

MMSE

21.72±3.94

17.34±5.04

30

3.523

0.001**

0.008**

0.000***

0.000***

TFF3

15.21±11.83

14.03±12.25

18.20±6.21

-2.668

0.006*

0.089

0.007**

0.005**

ChE
activity

7528±1573

7232±1254

7785±1962

-1.815

0.042*

0.882

0.067

0.028*

Hcy

16.18±4.96

18.21±5.72

10.45±3.19

3.478

0.002**

0.625

0.008**

0.006**

*p<0.05, **p<0.01, ***p<0.001. Kruskal-Wallis test for the comparison among PDD, VPD and normal subjects, Tukey’s post hoc analysis
for the comparison in PDD vs. VPD, PDD vs. Control, or VPD vs. Control.

Statistical analyses
All continuous variables, including age, UPDRS
(UPDRS-I, -II, -III and -IV), MMSE, NMSS, TFF3, ChE

activity and Hcy, are presented as their means ± SD. All
categorical variables, including gender, are presented as
percentages. Total scores for age, UPDRS, MMSE,
NMSS, CRP, TFF3, ChE activity and Hcy were counted
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by summing the single items. The statistical significance
of differences between the groups was assessed by Mann–
Whitney U test and Kruskal–Wallis test when the data
were not normally distributed; Student’s t-test was used
when the data were normally distributed. One-way
analysis of variance (One-way ANOVA) followed by
Tukey’s post-hoc analysis was conducted to compare
differences in TFF3/ChE activity/Hcy among normal
subjects and PDD and VPD patients, including PDD and
VPD sub-groups based on UPDRS(III) scores distribution.
Spearman’s rank correlation coefficients (rs) were

obtained to evaluate correlations among different clinical
parameters. A receiver operating characteristic (ROC)
analysis was conducted to assess the performance of
clinical biomarkers (TFF3, ChE activity and Hcy) as
diagnostic criteria for these diseases. Additionally, ROC
curves for the combination of TFF3, ChE activity and Hcy
were calculated as a possible better prognostic tool using
logistic regression analysis. P-values <0.05 were deemed
statistically significant and SPSS 13.0 (Chicago, IL, USA)
was used for all statistical analyses.

Table 3. Comparison of TFF3, Hcy and ChE activity between normal subjects and PDD patients according to genders.

PDD vs. Control
Variable
TFF3

ChE activity

Hcy

PDD (mean ±SD)

Value

p

Male

15.03±11.26

20.12±9.51

-2.558

0.009**b

Female

17.29±10.17

20.43±7.10

-2.911

0.006**a

Male

7596±1433

7736±1648

-2.083

0.038*a

Female

7680±1259

7839±1542

-1.915

0.026*b

Male

18.21±4.72

11.39±2.80

3.974

0.000***b

3.015

0.002*a

Female

14.59±5.73

PDD(Male) vs. (Female)

Control (mean ±SD)

10.74±2.25

Value

p

-2.976

0.003**a

-0.863

0.520b

3.239

0.003*a

*p<0.05, **p<0.01, ***p<0.001. a Mann-Whitney U-test. b Student’s t-test.

RESULTS
Patient Characteristics
This cross-sectional study consisted of 92 PDD patients,
82 VPD patients and 80 healthy subjects (Table 1). The
mean age of the VPD patients was higher than the mean
age of the PDD patients (Table 2) and the mean age of the
VPD patients was higher than the mean age of the normal
subjects (Table 2). There were no significant differences
in ages among the PDD patients and the healthy controls
(Table 2). Demographic and clinical data for all subjects
are shown in Table 1.
Comparisons of Age, MMSE, TFF3, ChE activity and
Hcy between PDD/VPD Patients and Healthy Subjects
In this study, the mean age for patients with VPD was
higher than that of the PDD patients (Table 2) and the
MMSE for patients with VPD was lower than that of PDD
patients (Table 2). Significant differences in serum levels
of TFF3/ChE activity/Hcy were found among the PDD
and VPD patients and the control subjects (Table 2).

Serum levels of TFF3 in PDD/VPD patients were lower
than in normal subjects (Table 2), while no significant
differences in TFF3 levels between PDD and VPD
patients were observed. Similarly, ChE activity levels in
patients with VPD were significantly lower than in the
healthy subjects (Table 2). Serum Hcy levels in PDD/VPD
patients were higher than in the normal subjects (Table 2),
but no significant differences in Hcy levels between PDD
and VPD patients were found.
When PDD and VPD patients and normal subjects
were divided into specific gender groups, the serum levels
of TFF3 in the male/female patients with PDD were lower
than those of the normal male/female subjects (Table 3).
Similarly, a significant decrease was observed in plasma
ChE activity between PDD male/female patients and
normal male/female subjects (Table 3). However, a
significant difference was observed in plasma Hcy levels
between PDD male/female patients and normal
male/female subjects (Table 3). Additionally, in PDD
patients, levels of TFF3 in male patients were lower than
in female patients (Table 3), while serum Hcy levels in
male patients were higher than those in female patients
with PDD (Table 3). There were no significant differences
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in serum ChE activity levels between male PDD patients
and female PDD patients (Table 3). Interestingly, our data
showed that serum TFF3 and ChE activity levels in
male/female VPD patients were significantly lower than
in male/female normal subjects (Table 4), while Hcy
serum levels were significantly higher than in
male/female normal subjects (Table 4). TFF3 levels in

male VPD patients were lower than in the female VPD
patients (Table 4), while serum Hcy levels in male VPD
patients were higher than those in female VPD patients
(Table 4). There were no significant differences in the
serum ChE activity levels between male VPD patients and
female VPD patients.

Table 4. Comparison of TFF3, Hcy and ChE activity between healthy subjects and VPD patients according to genders.

Variable
TFF3

ChE activity
Hcy

VPD vs. Control

VPD (mean ±SD)

Control (mean ±SD)

Value

p

Male

14.67±11.51

20.12±9.51

-3.956

0.000*a

Female

16.98±12.36

20.43±7.10

-3.579

0.002*b

Male

7286±1626

7736±1648

-2.066

0.032*b

Female

7351±1820

7839±1542

-2.017

0.041*a

Male

21.11±5.24

11.39±2.80

3.923

0.000***a

Female

16.27±4.19

10.74±2.25

3.381

0.000***b

VPD(Male) vs.
(Female)
Value
p
-3.241

0.004**a

-0.571

0.739b

2.939

0.003**b

*p<0.05, **p<0.01, ***p<0.001. a Mann–Whitney U-test. b Student’s t-test.

Comparison of TFF3, Hcy and ChE activity between
PDD and VPD patients according to genders and
UPDRS-III scores

Correlations among TFF3/ChE activity/Hcy levels and
age, UPDRS, H&Y, MMSE and NMSS (total/domain) in
PDD and VPD Patients

We found serum Hcy levels in male VPD patients were
significantly higher than those in male PDD patients
(Table 5), while serum TFF3 and ChE activity didn’t
display such gender-associated differences between PDD
and VPD patients (Table 5). When PDD and VPD groups
were divided into three sub-groups based on UPDRS-III
scores respectively, we found serum TFF3 levels were
significantly lower in VPD patients than those in PDD
patients in UPDRS(III)≤30 and 31<UPDRS(III)<50 subgroups. Besides, our data showed that serum ChE activity
were significantly lower in VPD patients than those in
PDD patients in 31<UPDRS(III)<50 and UPDRS(III)>50
sub-groups (Table 5).

To evaluate correlations between the severity of the
disease and clinical variables in PDD and VPD patients,
we conducted Spearman’s correlation analysis among
mediator variables and various assessments. We found
TFF3 level was negatively correlated with UPDRS,
UPDRS(Ⅲ) and H&Y staging and positively correlated
with MMSE scores in PDD and VPD patients (Table 7).
Although no significant correlations were observed for
TFF3 and UPDRS(I), TFF3 and UPDRS(II), TFF3 and
UPDRS(IV) or TFF3 and some of burdens of NMSS,
there were significant correlations between TFF3 and
NMS burdens of mood, attention/memory, as well as
gastrointestinal distress in PDD and VPD patients (Table
7).
Besides, serum Hcy was positively correlated with
H&Y staging and negatively correlated with MMSE
scores in PDD and VPD patients (Table 7). Specifically,
positive correlations were observed between Hcy and
NMSS-cardiovascular burden in PDD and VPD patients,
and between Hcy and NMSS-attention/memory burden in
VPD patients (Table 7). There were, however, no
significant correlations between Hcy and UPDRS, Hcy
and UPDRS(I), Hcy and UPDRS(II), Hcy and
UPDRS(Ⅲ), Hcy and UPDRS(IV) or Hcy and NMSS in
either PDD/VPD patients.

Correlation analyses among TFF3/ChE activity and
Hcy Levels in PDD and VPD Patients
To evaluate the relationships between TFF3/ChE activity
and Hcy Levels in PDD and VPD patients, we conducted
Spearman’s correlation analysis. We found a significant
negative correlation between TFF3 and Hcy Levels in
PDD and VPD patients (Table 6, Fig. 1). Similarly, a
profound inverse correlation between ChE activity and
Hcy levels was observed in PDD and VPD patients (Table
6, Fig. 1).
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Figure 1. Correlation analysis between TFF3/ChE activity and Hcy Levels in PDD and VPD patients. A significant negative
correlation between (A) TFF3 and Hcy Levels in PDD patients (rs =-0.799, ***p<0.001); (B) ChE activity and Hcy Levels in PDD
patients (rs =-0.732, ***p<0.001). (C) TFF3 and Hcy Levels in VPD patients (rs =-0.771, ***p<0.001). (D) ChE activity and Hcy
Levels in VPD patients (rs =-0.713, ***p<0.001).

Additionally, we found serum ChE activity was
negatively correlated with UPDRS, UPDRS(Ⅲ), H&Y
staging and positively correlated with MMSE scores in
PDD and VPD patients (Table 7). There were negative
correlations between ChE activity and the NMSScardiovascular burden in VPD patients, and between ChE
activity and NMS burdens of mood and attention/memory
in PDD and VPD patients (Table 7). No significant
correlations were observed between ChE activity and
UPDRS (I/II/IV), ChE activity and NMSS in PDD and
VPD patients. Interestingly, our results also showed that,
although patients with PDD and VPD were treated with
L-dopa, this L-dopa treatment was not significantly
correlated to their serum levels of TFF3, Hcy or ChE
activity (Table 7). This finding strongly suggests that Ldopa medication in PDD and VPD patients does not
influence the validity of TFF3/Hcy/ChE activity
assessment in those PDD and VPD patients.

ROC Curves for TFF3, ChE activity and Hcy in the
Diagnosis of PDD and VPD
ROC curves were constructed to explore whether TFF3,
ChE activity and Hcy levels could provide credible
discrimination between PDD patients and normal subjects.
ROC curves for TFF3 analysis revealed that an area under
the curve (AUC) value of 0.778 (Fig. 2A) was appropriate;
the cut off was at 15.39 μmol/L, with a sensitivity of 62%
and specificity of 90%. The AUC for Hcy was 0.690 (Fig.
2C); the cut off was at 16.82 μmol/L, with a sensitivity of
54% and specificity of 86%. However, the AUC for ChE
activity was 0.516 (Fig. 2B), indicating no significant
differences. The AUC for the combination of TFF3, Hcy
and ChE activity was 0.880 (Fig. 2D), with a sensitivity
of 68% and a specificity of 89% at a cutoff of 0.59 on the
predicted risk algorithm.
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Table 5. Comparison of TFF3, Hcy and ChE activity between PDD and VPD patients according to genders and UPDRSIII scores.
PDD
Mean ±SD

Variable
TFF3
Gender
UPDRS(III)

ChE activity
Gender
UPDRS(III)

Hcy
Gender
UPDRS(III)

VPD
Mean ±SD

Value

PDD vs. VPD
p

Male
Female
UPDRS(III)≤30
31<UPDRS(III)<50
UPDRS(III)≤30

15.03±11.26
17.29±10.17
16.85±10.33
15.74±10.29
14.33±9.81

14.67±11.51
16.98±12.36
15.37±10.16
14.16±10.03
13.85±9.27

0.153
0.902
2.629
3.140
1.218

0.8786
0.123
0.011a*
0.003 a**
0.082

Male
Female
UPDRS(III)≤30
31<UPDRS(III)<50
UPDRS(III)>50

7596±1433
7680±1259
8027±1003
7829±1282
7462±1291

7286±1626
7351±1820
7829±1579
7320±1050
7057±1331

0.982
0.951
1.883
2.145
2.335

0.3285
0.345
0.075
0.037 a*
0.020 a*

Male
Female
UPDRS(III)≤30
31<UPDRS(III)<50
UPDRS(III)>50

18.21±4.72
14.59±5.73
17.82±3.94
16.35±4.31
15.78±4.60

21.11±5.24
16.27±4.19
19.33±4.91
18.56±4.43
17.41±3.89

2.832
1.476
0.232
0.537
0.891

0.006b**
0.144
0.713
0.281
0.371

*p<0.05, **p<0.01, ***p<0.001. a Tukey’s post hoc analysis. b Mann-Whitney U-test.

Furthermore, in VPD patients, the AUC for TFF3
was 0.748 (Fig. 2E); the cut-off was at 14.21 µmol/L, with
a sensitivity of 60% and a specificity of 75%. The AUC
for Hcy was 0.623 (Fig. 2G); the cut off was at 18.36
μmol/L, with a sensitivity of 48% and specificity of 66%.
However, the AUC for ChE activity was 0.567 (Fig. 2F);
the cut off was at 7250 U/L, with a sensitivity of 44% and
specificity of 56%. The AUC for the combination of TFF3,

Hcy and ChE activity was 0.846 (Fig. 2H), with a
sensitivity of 57% and a specificity of 76% at a cutoff of
0.53 on the predicted risk algorithm. These data indicate
that the combination variable was more robust than TFF3,
ChE activity or Hcy alone in distinguishing PDD and
VPD patients from healthy controls.

Figure 2. ROC curves to evaluate the
utility of serum levels of TFF3, ChE
activity and Hcy Levels for the
discrimination of PDD/VPD patients from
healthy controls. (A-D) The AUC of ROC
curves for discrimination of PDD patients
from healthy controls (A) TFF3, (B) ChE
activity, and (C) Hcy were 0.778 (95%CI:
0.706–0.850, *p=0.037), 0.516 (95%CI:
0.423–0.609, p=0.737), and 0.690 (95%CI:
0.606–0.774, *p=0.043), respectively. The
AUC of (D) TFF3+ChE activity+Hcy was
0.880 (95%CI: 0.828–0.932, *p=0.027). (EH)
The AUC
of
ROC
curves
for discrimination of VPD patients from
healthy controls. (E) TFF3, (F) ChE activity,
and (G) Hcy were 0.748 (95%CI: 0.671–
0.826, *p=0.040), 0.567 (95%CI: 0.475–
0.660, *p=0.047), and 0.623 (95%CI: 0.533–
0.713, *p=0.046), respectively. The AUC
of (H) TFF3+ChE activity+Hcy was 0.846
(95%CI:0.785–0.908, *p=0.031).

DISCUSSION
We found several important results in this study. First, we
found a pronounced decrease in the serum levels of TFF3

and ChE activity and an increase in the levels of Hcy in
PDD/VPD patients when compared to healthy subjects.
Second, increased serum Hcy levels were significantly
and inversely correlated with decreased TFF3/ChE

Aging and Disease • Volume 9, Number 1, February 2018

58

TFF3 and ChE activity as markers for PDD and VPD

Zhou J. et al

activity levels. Third, there were significant correlations
between TFF3/ChE/Hcy levels and the severity of
PDD/VPD, including motor dysfunction, declining
cognition and mood/gastrointestinal symptoms. Lastly,
our ROC curve analysis strongly indicated that the
combination of TFF3, ChE activity and Hcy could
significantly discriminate PDD/VPD patients from
healthy subjects and could be applied as a potential
screening instrument for disease diagnosis. To our

knowledge, this is the first study to explore changes in the
serum levels of TFF3 and ChE activity in PDD/VPD
patients and to evaluate the potential relationships
between TFF3 and the dementia. The interesting finding
of inversed correlation between serum TFF3/ChE activity
and Hcy levels may shed light on the underlying
pathogenesis of PDD and VPD.

Figure 3. MRI images in normal controls and PDD and VPD patients. (A) Normal subjects, (B) PDD patients,
(C) VPD patients. The extent of white matter hyperintensities and multiple infarctions in the basal ganglia in the VPD
patients are shown in T2-weighted and FLAIR images. Arrows indicate the infarction.
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Table 6. Spearman’s rank correlation coefficient (rs) and p-values between TFF3/ChE activity and Hcy
Levels in PDD and VPD patients.
Variable
TFF3
ChE activity

Hcy in PDD
r
-0.799
-0.732

Hcy in VPD
p

r

p

0.000***

-0.771

0.000***

0.000***

-0.713

0.000***

*p<0.05, **p<0.01, ***p<0.001. rs, Spearman’s rank correlation coefficient.

Over the past few years, comparisons of VPD and
PDD patients have received significant attention for the
diagnosis, therapy and evaluation of their status [36, 4548]. We found that NMS (including cardiovascular, sleep
and mood disorders) are very common in patients with
PDD and VPD, with a prevalence of NMS in the group of
100% and an NMSS for PDD (Table 1) consistent with
previous reports [39, 49]. Interestingly, as shown in
Tables 1 and 2, our patients with VPD exhibited shorter
disease durations and older ages at onset than those
patients with PDD. This finding implies that Chinese VPD
patients may develop symptoms later in life, but they may
experience deterioration faster than PDD patients.
Additionally, a later age at onset of VP would favor a
vascular cause [31]. Significant reductions in scores on
the MMSE were observed in VPD patients when
compared to the PDD group (Table 2). This result
demonstrates that compared to PDD subjects, Chinese
VPD patients had already undergone a greater decline in
cognitive function by the time they visited the neurologist.
This result is in agreement with Zijlmans’ finding [36] and
implies that our VPD patients may have more subcortical
lesions than the patients with PDD and these subcortical
vascular ischemic lesions may have led to their more
rapidly declining cognition [7].
Until now, the roles of TFF3 in the central nervous
system have not been adequately explored. TFF3 has been
previously documented to be associated with cognitive
functioning, including vascular epithelial restitution and
suppressing inflammation in the central nervous system
[16-19]. TFF3 levels in patients with PDD/VPD were
significantly lower than in the healthy subjects, similar to
findings from other neurodegenerative diseases such as
AD [17]. When compared to healthy controls, these
decreased TFF3 levels in PDD/VPD patients imply that
TFF3 contributes to the pathophysiological mechanisms
of disease development. Serum ChE activity reflects
metabolic alterations associated with dementia [50].
Szilagyi et al. described lowered serum and CSF ChE
activity in patients with dementia [51]. We also found that
serum ChE activity in VPD patients was significantly
lower than that in healthy subjects. Although serum ChE
activity in PDD patients was lower than in healthy

subjects, the difference did not reach significance. One
possible explanation may be that these declines in ChE
activity in the CNS are not low enough to affect peripheral
concentrations in PDD patients [52]. It has been well
documented that altered TFF3 and ChE activity are
associated with a higher risk of AD. Low CSF TFF3 levels
are associated with both the rate of cognitive decline and
the rate of hippocampal atrophy and ventricular expansion
[17]. Several lines of evidence have indicated that
significantly lower cortical and thalamic AChE activity
are associated with declines in cognitive impairment [52].
Therefore, in the diagnosis and evaluation of PDD and
VPD, TFF3 and ChE activity could be used as potential
markers.
Previous studies have demonstrated that elevated
plasma Hcy levels represent a risk factor for declining
cognition and dementia in the general population [22, 53],
but Hcy levels have also been associated with mild
cognitive impairment (MCI), AD, PD, and vascular
dementia [20, 23, 54, 55]. Similar results have been
observed in PDD and VPD patients. These findings
strongly suggest that higher levels of Hcy may contribute
to the severity of PDD and VPD. Therefore, Hcy may be
a possible target in the treatment of PDD and VPD [54,
56].
After dividing subjects by gender, we noticed (Table
4) that serum TFF3 levels in male PDD/VPD patients
were significantly lower than female PDD/VPD patients,
while serum Hcy levels in male PDD/VPD patients were
significantly higher than in female PDD/VPD patients.
This finding suggests that serum TFF3 and Hcy may be
more useful in evaluating PDD/VPD in men. These biophysiological associations between gender-specific
hormones and TFF3/Hcy may be partly attributable to
higher occurrences of PDD/VPD in men [57, 58].
Interestingly, we observed no significant difference
in serum TFF3, ChE activity and Hcy levels between PDD
and VPD patients. This finding may be due to the similar
neuro-pathogenesis between PDD and VPD, i.e. those
three factors participating the vascular epithelial
restitution and suppressing inflammation in the brain [18,
19, 22, 26, 29]. We next explored the differences between
PDD and VPD patients. Although the three serum
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biomarkers displayed no difference between these two
groups, serum Hcy levels were higher in male VPD
patients than those in male PDD patients (Table 5),
implying Hcy may be more suitable to evaluate the status
and more closely correlated to the neuro-pathogenesis in
male VPD patients [58]. When PDD and VPD groups
were divided into three sub-groups based on UPDRS-III
scores respectively, we found serum TFF3 levels were
significantly lower in VPD patients than those in PDD
patients in UPDRS(III)≤30 and 31<UPDRS(III)<50 subgroups. This finding suggests that in VPD patients,
especially in the early-mid stage, micro-vascular

impairment and inflammatory response are more
prominent, as indicated by the lower levels of serum TFF3
in VPD compared to PDD [4, 6, 18, 19]. Interestingly, we
noticed that serum ChE activity was significantly lower in
VPD patients than those in PDD patients in
31<UPDRS(III)<50 and UPDRS(III)>50 sub-groups
(Table 5). This result strongly implies that during midlater stage, cerebral function is more impaired and more
neurons are damaged in VPD compared to PDD, as shown
by lower ChE activity in VPD [25, 26]. Whether serum
TFF3 and ChE activity could be used in evaluating the
status of VPD and PDD needs further exploration.

Table 7. Spearman’s rank correlation coefficient (rs) and p-values between clinical variables and H&Y, MMSE,
NMSS(total/domain) s in PDD and VPD patients.
Variable

ChE activity
(PDD)

Hcy (PDD)

r

p

r

p

r

p

r

p

r

p

r

p

0.423

0.091

0.138

0.550

0.168

0.433

0.474

0.087

0.257

0.375

0.134

0.647

UPDRS

-0.126**

0.007

0.134

0.053

-0.319*

0.019 -0.795**

0.001

0.193

0.195

-0.367* 0.015

Up(Ⅰ)

-0.096

0.521

0.169

0.256

-0.270

0.237

0.535

0.030

0.220

-0.463

0.096

Up(Ⅱ)

-0.091

0.541

0.173

0.247

-0.134

0.367

-0.458

0.065

0.143

0.289

-0.197

0.355

Up(Ⅲ)

-0.327*

0.025

0.283

0.213

-0.397*

0.015

-0.578*

0.015

0.073

0.274

-0.298* 0.017

Up(Ⅳ)

-0.052

0.645

0.042

0.712

-0.037

0.742

-0.266

0.106

0.185

0.079

-0.037

H&Y

-0.315*

0.031

0.342*

0.019

-0.269*

0.025

-0.206*

0.047

0.306*

0.026

-0.379* 0.022

MMSE

0.378**

0.009

-0.364*

0.012

0.358*

0.014

0.249*

0.026 -0.339*

0.030

0.418** 0.008

NMSS

0.241

0.103

0.006

0.978

0.065

0.681

0.086

0.074

0.127

0.071

Cardiovascular

-0.205

0.168

0.359*

0.015

-0.201

0.178

-0.094

0.138

0.115*

0.014

-0.207* 0.048

Sleep/Fatigue

-0.478

0.084

0.417

0.064

-0.057

0.755

-0.026

0.616

0.085

0.218

-0.041

Mood

-0.351*

0.015

0.067

0.681

-0.391** 0.001

-0.343*

0.028

0.070

0.601 -0.393** 0.001

-0.058

0.218

0.080

0.253

–0.185

0.105

-0.074

0.646

0.054

0.392

–0.035

-0.118*

0.014

0.009

0.950

–0.249* 0.026

-0.243*

0.029

0.362*

0.013

-0.341* 0.034

Gastrointestina

-0.668**

0.009

-0.141

0.341

-0.069

0.645 -0.769**

0.001

0.113

0.103

-0.112

0.075

Urinar

-0.045

0.763

0.018

0.915

-0.021

0.894

-0.063

0.190

0.054

0.462

-0.205

0.198

Sexual function

-0.219

0.140

0.029

0.846

–0.227

0.164

-0.083

0.071

0.073

0.301

-0.250

0.115

Miscellaneous

-0.044

0.350

-0.007

0.919

–0.208

0.155

-0.410

0.081

0.230

0.119

-0.104

0.487

Daily dose of LDopa (mg)

-0.071

0.130

0.131

0.058

-0.100

0.497

-0.031

0.502

0.027

0.695

-0.002

0.972

Age

Perceptual
problem
Attention/
memory

TFF3 (VPD)

-0.133

Hcy (VPD)

ChE activity
(VPD)

TFF3 (PDD)

0.049

0.745

0.462

0.526

0.831

*p<0.05, **p<0.01,***p<0.001. rs, Spearman’s rank correlation coefficient; UPDRS, Unified Parkinson’s disease rating scale; H&Y, the modified Hoehn
and Yahr staging scale; MMSE, mini-mental state examination; NMSS, non-motor symptoms scale for Parkinson’s disease.

Aging and Disease • Volume 9, Number 1, February 2018

61

TFF3 and ChE activity as markers for PDD and VPD

Zhou J. et al

TFF3 and ChE activity showed strong negative
correlations with UPDRS, H&Y and NMSS (mood and
attention/memory) and positive correlations with MMSE
in PDD/VPD patients. This finding strongly suggests that
serum levels of TFF3 and ChE activity may significantly
influence motor and non-motor dysfunction in PDD and
VPD patients. Previous studies have indicated that TFF3
deficiency presents with a significant forelimb motor
dysfunction in experimental ischemic injury mice [59].
Significant correlations were also observed between
decreased cortical AChE activity and higher total UPDRS
scores in patients with PD [52, 60]. These findings
suggested that the ascending cholinergic system from the
nucleus basalis of Meynert to the cerebral cortex is
impaired more severely as PD advances. We also found
similar findings for ChE activity, with significant
correlations between lower ChE activity and higher
UPDRS/UPDRS III scores in PDD and VPD patients.
Specifically, TFF3 and ChE activity showed negative
associations with mood and attention/memory and
positive correlations with MMSE in PDD/VPD patients,
further demonstrating that these two dysfunctions could
be important targets for disease evaluation using plasma
levels of TFF3 and ChE activity. Consistent with our
notions, several studies have shown that TFF3 deficiency
and low levels of ChE activity are correlated with mood,
memory deterioration and cognitive function [16, 50]. We
also noticed plasma levels of TFF3 showed robust
associations with the gastrointestinal domain in PDD and
VPD patients, implying that TFF3 could be a high-risk
factor for gastrointestinal disease. Interestingly, Hcy
demonstrated strong positive correlations with H&Y and
NMSS (cardiovascular domain) and a negative correlation
with MMSE in PDD/VPD patients, implying that plasma
Hcy levels might be used to evaluate the severity of
cognitive status of PDD and VPD patients [61, 62].
Since several lines of evidence show that TFF3, ChE
and Hcy may be involved in the pathogenesis of dementia
[16, 22, 23, 26], we specifically explored the relationships
among serum TFF3, ChE and Hcy. In the current study,
we noticed a significant and inverse correlation between
Hcy and TFF3/ChE activity in PDD and VPD patients
(Table 6, Figure 1). Previous studies have indicated that
elevated plasma Hcy increases the risk of dementia by
impacting cerebrovascular pathology [5, 6, 63, 64]. These
higher levels of Hcy in PDD/VPD patients may damage
neuron and vascular endothelial cells in the brain,
inducing neuroinflammation [23, 65, 66]. High levels of
Hcy could break down the blood brain barrier (BBB) and
lead to cerebrovascular dysfunction, which subsequently
modulates the activities of enzymes and neuropeptides
and influences hippocampal volume in the
pathophysiological processes of dementia [67-69]. It has
been shown that Hcy could stimulate superoxide and

hydrogen peroxide generation in vivo and in vitro [70] and
that ChEs activities are inhibited by high level of Hcy
mediated by the generation of free radical formation [7173]. Multiple lines of evidence indicate that TFF3 exerts
protective effects via promoting vascular epithelial
restitution and anti-inflammation，which is opposite to
the effects of Hcy [17-19]. Therefore, we propose that
Hcy may negatively influence cognitive functioning in
PDD/VPD patients via altering cerebrovascular pathology
and subsequently downregulating TFF3/ChE activity,
subsequently leading to impaired cognition in PDD and
VPD. Based on this finding, we hypothesize that the
combination of TFF3, ChE activity and Hcy would be an
early pathophysiological marker for cognitive
dysfunction in VP and PD patients.
Our ROC data indicate an acceptable sensitivity and
specificity for TFF3 and ChE activity in the potential
discrimination of PDD/VPD patients from normal
subjects. Notably, TFF3 displays more reliable
discrimination when compared to ChE activity (Figures
2A, D). Moreover, one of the most notable findings in the
current study showed that the combination of TFF3 and
ChE activity and Hcy exhibited better discriminatory
ability in PDD/VPD, in comparison to TFF3, ChE activity
or Hcy alone. With the use of the serum TFF3 and ChE
activity as screening tools, clinicians could potential use
these as a combined biomarker to potentially detect
PDD/VPD.
There are several limitations to this study: (1) a small
number of participants (92 PDD patients, 82 VPD patients,
and 80 healthy subjects) were recruited. Therefore, it is
necessary to conduct a large population study in the future;
(2) most patients with PDD/VPD were at middle-late
stages of the disease, with a high median stage on the
H&Y scale and a relatively low MMSE score (21.72 for
PDD patients, 17.34 for VPD patients); (3) our study is a
cross-sectional study. Therefore, longitudinal cohort
studies are needed in the future to explore the alterations
of the three serum biomarkers (TFF3, ChE and Hcy)
during the disease progression in PDD and VPD; (4)
genetic factors such as the TFF3 genotype and folate or
cholinesterase inhibitor administration were not
considered in this study; (5) to validate and complete the
questionnaire, we chose only PDD and VPD patients with
sufficient cognitive ability, which significantly narrowed
the study population. The above criteria (1–5) in the
population chosen may have resulted in a bias for serum
levels of TFF3, ChE activity and Hcy in PDD/VPD
patients. Therefore, it is necessary to conduct a large
population study in the future.
In summary, the current study supports the notion
that decreased serum TFF3/ChE activity and increased
Hcy may be related to the pathophysiology of PDD and
VPD. Based on this study, it is reasonable to speculate that
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high levels of serum Hcy may negatively influence
cognitive function in PDD/VPD patients through various
mechanisms, including inducing cerebrovascular
pathology and subsequent downregulation of TFF3/ChE
activity. Furthermore, low levels of serum TFF3 and ChE
activity combined with high levels of serum Hcy may
predispose patients to the progressive stages in both motor
and non-motor dysfunctions. Based on our findings, we
propose that serum TFF3, ChE activity and Hcy may
underlie the pathophysiological mechanisms of
PDD/VPD and could be used to evaluate the severity of
these diseases.
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